| Name | Anselamimab |
|---|
| Description | Anselamimab (CAEL-101) a humanized IgG1-κ anti-Amyloid fibrils antibody targeting to serum amyloid A1 (SAA1)[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Serum amyloid A1 (SAA1) |
| References |
[1]. Palladini G, et al. How I treat AL amyloidosis. Blood. 2022 May 12;139(19):2918-2930. |
| No Any Chemical & Physical Properties |